Toxoplasma gondii F-actin forms an extensive filamentous network required for material exchange and parasite maturation

  1. Javier Periz
  2. Jamie Whitelaw
  3. Clare Harding
  4. Simon Gras
  5. Mario Igor Del Rosario Minina
  6. Fernanda Latorre-Barragan
  7. Leandro Lemgruber
  8. Madita Alice Reimer
  9. Robert Insall
  10. Aoife Heaslip  Is a corresponding author
  11. Markus Meissner  Is a corresponding author
  1. University of Glasgow, United Kingdom
  2. Cancer Research UK Beatson Institute, United Kingdom
  3. University of Vermont, United States

Abstract

Apicomplexan actin is important during the parasite's life cycle. Its polymerization kinetics are unusual, permitting only short, unstable F-actin filaments. It has not been possible to study actin in vivo and so its physiological roles have remained obscure, leading to models distinct from conventional actin behaviour. Here a modified version of the commercially available Actin-Chromobody® was tested as a novel tool for visualising F-actin dynamics in Toxoplasma gondii. Cb labels filamentous actin structures within the parasite cytosol and labels an extensive F-actin network that connects parasites within the parasitophorous vacuole and allows vesicles to be exchanged between parasites. In the absence of actin, parasites lack a residual body and inter-parasite connections and grow in an asynchronous and disorganized manner. Collectively, these data identify new roles for actin in the intracellular phase of the parasites lytic cycle and provide a robust new tool for imaging parasitic F-actin dynamics.

Article and author information

Author details

  1. Javier Periz

    Division of Infection and Immunity, Institute of Biomedical Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Jamie Whitelaw

    Division of Infection and Immunity, Institute of Biomedical Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Clare Harding

    Division of Infection and Immunity, Institute of Biomedical Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Simon Gras

    Division of Infection and Immunity, Institute of Biomedical Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Mario Igor Del Rosario Minina

    Division of Infection and Immunity, Institute of Biomedical Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Fernanda Latorre-Barragan

    Division of Infection and Immunity, Institute of Biomedical Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Leandro Lemgruber

    Division of Infection and Immunity, Institute of Biomedical Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. Madita Alice Reimer

    Division of Infection and Immunity, Institute of Biomedical Life Sciences, University of Glasgow, Glasgow, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Robert Insall

    Cancer Research UK Beatson Institute, Bearsden, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Aoife Heaslip

    Department of Molecular Physiology and Biophysics Burlington, University of Vermont, Vermont, United States
    For correspondence
    aoife.heaslip@uconn.edu
    Competing interests
    The authors declare that no competing interests exist.
  11. Markus Meissner

    Division of Infection and Immunity, Institute of Biomedical Life Sciences, University of Glasgow, Glasgow, United Kingdom
    For correspondence
    markus.meissner@glasgow.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4816-5221

Funding

Wellcome (087582/Z/08/Z)

  • Markus Meissner

H2020 European Research Council (ERC-2012-StG 309255-EndoTox)

  • Markus Meissner

Wellcome (WT103972AIA)

  • Clare Harding

National Institute for Health Research (AI121885)

  • Aoife Heaslip

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Periz et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,590
    views
  • 759
    downloads
  • 108
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

Share this article

https://doi.org/10.7554/eLife.24119

Further reading

  1. A parasite called Toxoplasma gondii builds a scaffold inside human and other animal cells to help it multiply and cause disease.

    1. Cancer Biology
    2. Cell Biology
    Brooke A Conti, Leo Novikov ... Mariano Oppikofer
    Research Article

    DNA base lesions, such as incorporation of uracil into DNA or base mismatches, can be mutagenic and toxic to replicating cells. To discover factors in repair of genomic uracil, we performed a CRISPR knockout screen in the presence of floxuridine, a chemotherapeutic agent that incorporates uracil and fluorouracil into DNA. We identified known factors, such as uracil DNA N-glycosylase (UNG), and unknown factors, such as the N6-adenosine methyltransferase, METTL3, as required to overcome floxuridine-driven cytotoxicity. Visualized with immunofluorescence, the product of METTL3 activity, N6-methyladenosine, formed nuclear foci in cells treated with floxuridine. The observed N6-methyladenosine was embedded in DNA, called 6mA, and these results were confirmed using an orthogonal approach, liquid chromatography coupled to tandem mass spectrometry. METTL3 and 6mA were required for repair of lesions driven by additional base-damaging agents, including raltitrexed, gemcitabine, and hydroxyurea. Our results establish a role for METTL3 and 6mA in promoting genome stability in mammalian cells, especially in response to base damage.